These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29368050)

  • 41. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
    van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
    J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
    Li J; Tan Y; Li K; Hui AM; Wu Z; Han P; Wei Z; Qiu J; Diao L; Wang X
    Adv Ther; 2023 Mar; 40(3):1074-1086. PubMed ID: 36627544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.
    Krishna G; Moton A; Ma L; Medlock MM; McLeod J
    Antimicrob Agents Chemother; 2009 Mar; 53(3):958-66. PubMed ID: 19075045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
    Dean E; Banerji U; Schellens JHM; Krebs MG; Jimenez B; van Brummelen E; Bailey C; Casson E; Cripps D; Cullberg M; Evans S; Foxley A; Lindemann J; Rugman P; Taylor N; Turner G; Yates J; Lawrence P
    Cancer Chemother Pharmacol; 2018 May; 81(5):873-883. PubMed ID: 29541803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-Dose Pharmacokinetic Properties and Relative Bioavailability of Different Formulations of Posaconazole Oral Suspension in Healthy Volunteers.
    Vuletić L; Herceg M; Ferderber K; Tunjić I; Rizea-Savu S; Duna SN; Cetina-Čižmek B; Filipović-Grčić J
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):827-836. PubMed ID: 30536797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
    Mascarenhas J; Passamonti F; Burbury K; El-Galaly TC; Gerds A; Gupta V; Higgins B; Wonde K; Jamois C; Kovic B; Huw LY; Katakam S; Maffioli M; Mesa R; Palmer J; Bellini M; Ross DM; Vannucchi AM; Yacoub A
    Blood Adv; 2022 Feb; 6(4):1162-1174. PubMed ID: 34933330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition.
    Fishlock D; Diodone R; Hildbrand S; Kuhn B; Mössner C; Peters C; Rege PD; Rimmler G; Schantz M
    Chimia (Aarau); 2018 Aug; 72(7):492-500. PubMed ID: 30158012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
    Menssen HD; Quinlan M; Kemp C; Tian X
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):385-394. PubMed ID: 30059193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
    Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
    Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
    Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
    Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
    Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions.
    Gao X; Ndongo MN; Checchio TM; Cook J; Duncan B; LaBadie RR
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):74-80. PubMed ID: 27128005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.